CSIMarket
 
Sana Biotechnology Inc   (NASDAQ: SANA)
Other Ticker:  
 
 
Price: $2.8400 $0.09 3.085%
Day's High: $2.87 Week Perf: -12.88 %
Day's Low: $ 2.62 30 Day Perf: -17.92 %
Volume (M): 2,044 52 Wk High: $ 12.00
Volume (M$): $ 5,804 52 Wk Avg: $5.61
Open: $2.69 52 Wk Low: $1.52



 Market Capitalization (Millions $) 669
 Shares Outstanding (Millions) 235
 Employees 300
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -306
 Cash Flow (TTM) (Millions $) -41
 Capital Exp. (TTM) (Millions $) 47

Sana Biotechnology Inc
Sana Biotechnology Inc is a biotechnology company that focuses on cell engineering to create and deliver transformative cures for patients suffering from various diseases. The company utilizes advancements in stem cell biology, gene editing technologies, and other cellular therapies to develop novel treatments. Sana Biotechnology aims to tackle complex and challenging diseases by engineering cells to repair, replace, and enhance the body's natural functions. Their goal is to provide patients with new, advanced therapies that have the potential to significantly improve their quality of life.


   Company Address: 188 East Blaine Street Seattle 98102 WA
   Company Phone Number: 701-7914   Stock Exchange / Ticker: NASDAQ SANA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
DNA   -9.94%    
IMCR   -1.37%    
MRNA   -9.15%    
NVAX   -5.32%    
RGNX   -14.59%    
RLAY   -16.63%    
• View Complete Report
   



Clinical Study

Heralding a New Era in Diabetes Treatment Immunosuppression-Free Islet Cell Transplantation,

Published Tue, Jan 7 2025 10:22 PM UTC

Transformative Progress in Type 1 Diabetes: The Promise of Immunosuppression-Free Islet Cell Transplantation In a groundbreaking advancement for the treatment of Type 1 diabetes, Sana Biotechnology recently announced positive clinical results from their innovative study on islet cell transplantation that circumvents the need for immunosuppression. This first-in-human study d...

Management Announcement

Sana Biotechnology?s High-Stakes Race: Fast-Tracks and Financial Challenges in Autoimmune Treatment Landscape,

Published Mon, Dec 2 2024 2:01 PM UTC

Sana Biotechnology s Bold Gambit: Fast Tracking into the Future of Autoimmune Treatments Amid Financial TurbulenceBy CSI Market In a move that could reshape the landscape of autoimmune disease treatment, Sana Biotechnology Inc. recently announced it has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for its investigational therapy SC...

Clinical Study

Harnessing Innovative Biotechnology for the Treatment of Autoimmune Diseases Sana Biotechnologys Strategic Focus on ...

Published Mon, Nov 4 2024 9:30 PM UTC

Abstract: Sana Biotechnology has embarked on an ambitious initiative to leverage groundbreaking therapeutic platforms to address type 1 diabetes and B-cell mediated autoimmune diseases. As clinical trials edge closer, this article delves into the details of Sana?s promising candidates, namely UP421, SC451, and SC291, while also exploring advances in the treatment of refrac...

Product Service News

Transforming Patient Care Dhaval Patel Appointed Chief Scientific Officer at Sana Biotechnology

Published Mon, Aug 26 2024 8:05 PM UTC

In a significant step toward enhancing its innovative capabilities, Sana Biotechnology, Inc. (NASDAQ: SANA), a pioneering company dedicated to reshaping medical possibilities through engineered cells, has announced the appointment of Dr. Dhaval Patel, M.D., Ph.D., as its new Executive Vice President and Chief Scientific Officer. The appointment, disclosed on August 26, 2024,...

Management Announcement

Sana Biotechnology's Groundbreaking Research Paves the Way for Neurodegenerative Disease Treatments

Published Tue, May 21 2024 1:01 PM UTC



In a recent publication in Nature Biotechnology, Sana Biotechnology has unveiled promising preclinical data showcasing the potential of pluripotent stem cell-derived human glial progenitor cell transplantation as a treatment for Huntington s disease and other glial-based neurodegenerative conditions. The study involved healthy human glial cells being successfully t...










Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com